List of SBIR/STTR awards granted to VenatoRx Pharmaceuticals
VenatoRx PharmaceuticalsName | Description | SBIR/STTR Award Recipient | Government Agency | Government Branch | Award Type | Contract Number (US Government) | Award Phase | Award Amount (USD) | Date Awarded | Official Website | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
A SBIR Phase II contract was awarded to VenatoRx Pharmaceuticals in May, 2021 for $1,000,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R44AI155308-01A1 | Phase II | 1,000,000 | May 24, 2021 | |||||||
A SBIR Phase I contract was awarded to VenatoRx Pharmaceuticals in December, 2020 for $252,813.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43AI157533-01 | Phase I | 252,813 | December 15, 2020 | |||||||
A SBIR Phase II contract was awarded to VenatoRx Pharmaceuticals in March, 2022 for $1,000,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R44AI170331-01 | Phase II | 1,000,000 | March 10, 2022 | |||||||
A SBIR Phase II contract was awarded to VenatoRx Pharmaceuticals in May, 2019 for $1,000,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 2R44AI118115-03 | Phase II | 1,000,000 | May 15, 2019 | |||||||
A SBIR Phase II contract was awarded to VenatoRx Pharmaceuticals in February, 2018 for $2,000,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 2R44AI120392-03A1 | Phase II | 2,000,000 | February 7, 2018 | |||||||
A SBIR Phase I contract was awarded to VenatoRx Pharmaceuticals in July, 2020 for $300,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43AI152672-01 | Phase I | 300,000 | July 15, 2020 | |||||||
A SBIR Phase II contract was awarded to VenatoRx Pharmaceuticals in July, 2016 for $3,462,890.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R44AI122421-01 | Phase II | 3,462,890 | July 5, 2016 | |||||||
A SBIR Phase I contract was awarded to VenatoRx Pharmaceuticals in July, 2016 for $690,598.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43AI124925-01A1 | Phase I | 690,598 | July 2, 2016 | |||||||
A SBIR Phase I contract was awarded to VenatoRx Pharmaceuticals in March, 2015 for $600,000.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43AI118115-01 | Phase I | 600,000 | March 1, 2015 | |||||||
A SBIR Phase I contract was awarded to VenatoRx Pharmaceuticals in June, 2014 for $599,200.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43AI109879-01 | Phase I | 599,200 | June 1, 2014 | |||||||
A SBIR Phase II contract was awarded to VenatoRx Pharmaceuticals in August, 2017 for $3,000,000.0 USD from the U.S. Department of Health & Human Services. | SBIR | 2R44AI109879-03A1 | Phase II | 3,000,000 | August 7, 2017 | |||||||
A SBIR Phase II contract was awarded to VenatoRx Pharmaceuticals in September, 2013 for $3,000,000.0 USD from the U.S. Department of Health & Human Services. | SBIR | 2R44AI096613-03A1 | Phase II | 3,000,000 | September 1, 2013 | |||||||
A SBIR Phase I contract was awarded to VenatoRx Pharmaceuticals in March, 2017 for $599,998.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43AI129009-01 | Phase I | 599,998 | March 15, 2017 | |||||||
A SBIR Phase II contract was awarded to VenatoRx Pharmaceuticals in August, 2013 for $3,000,000.0 USD from the U.S. Department of Health & Human Services. | SBIR | 2R44AI096679-03 | Phase II | 3,000,000 | August 1, 2013 | |||||||
A SBIR Phase I contract was awarded to VenatoRx Pharmaceuticals in June, 2015 for $600,000.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43AI120392-01 | Phase I | 600,000 | June 15, 2015 | |||||||
A SBIR Phase I contract was awarded to VenatoRx Pharmaceuticals for $600,000.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43AI096679-01 | Phase I | 600,000 | ||||||||
A SBIR Phase I contract was awarded to VenatoRx Pharmaceuticals in July, 2023 for $300,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43AI179443-01 | Phase I | 300,000 | July 24, 2023 | |||||||
A SBIR Phase II contract was awarded to VenatoRx Pharmaceuticals in June, 2023 for $1,000,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R44AI177015-01 | Phase II | 1,000,000 | June 7, 2023 |
